

Correction

Correction: MET Kinase Inhibitor SGX523 Synergizes with Epidermal Growth Factor Receptor Inhibitor Erlotinib in a Hepatocyte Growth Factor–Dependent Fashion to Suppress Carcinoma Growth

In this article (Cancer Res 2010;70:6880–90), which was published in the September 1, 2010 issue of *Cancer Research* (1), there are typographical errors in Table 1. A corrected version of the table is provided below.

Table 1. Growth advantage of human carcinoma cell lines in the human HGF^{tg}-SCID mouse model

Cell line	Cancer type	Met expression	Mouse strain	Tumor volume, average \pm standard error, mm ³	Mice with tumor/total mice inoculated	t test, P value	Days postinoculation (end point)	Cells injected/mouse
H596	Lung	++	Control SCID	0 \pm 0	0/10 ^a	0.005	49	5 \times 10 ⁵
			HGF ^{tg} -SCID	1,334 \pm 464	10/10			
H1373	Lung	++++	Control SCID	1,076 \pm 236	9/10	0.01	36	5 \times 10 ⁵
			HGF ^{tg} -SCID	1,825 \pm 194	10/10			
Colo205	Colon	+	Control SCID	806 \pm 122	15/15	0.04	29	1 \times 10 ⁶
			HGF ^{tg} -SCID	1,144 \pm 146	14/15			
DLD1	Colon	+	Control SCID	691 \pm 111	15/15	0.0002	36	1 \times 10 ⁶
			HGF ^{tg} -SCID	1,419 \pm 141	15/15			
HT-29	Colon	++	Control SCID	787 \pm 151	14/15	0.004	29	1 \times 10 ⁶
			HGF ^{tg} -SCID	1,351 \pm 130	15/15			
SW480	Colon	+	Control SCID	823 \pm 143	15/15	0.002	32	2 \times 10 ⁶
			HGF ^{tg} -SCID	1,576 \pm 195	15/15			
HCC1954	Breast	+++	Control SCID	31 \pm 15	5/13	0.004	60	1 \times 10 ⁶
			HGF ^{tg} -SCID	1,154 \pm 378	14/14			
MDA-MB-231	Breast	+	Control SCID	474 \pm 200	12/12	0.035	46	1 \times 10 ⁶
			HGF ^{tg} -SCID	1,104 \pm 245	12/14			
MDA-MB-435	Melanoma ^b	+	Control SCID	1,003 \pm 210	14/15	0.016	98	1 \times 10 ⁶
			HGF ^{tg} -SCID	1,662 \pm 204	14/14			
MKN-45	Gastric	+++++	Control SCID	706 \pm 113	14/15	0.008	28	1 \times 10 ⁶
			HGF ^{tg} -SCID	1,420 \pm 256	15/15			
NC1-N87	Gastric	+	Control SCID	358 \pm 114	13/14	0.05	60	1 \times 10 ⁶
			HGF ^{tg} -SCID	952 \pm 334	14/14			
786-0	Kidney	++	Control SCID	532 \pm 75	14/15	0.0002	69	5 \times 10 ⁵
			HGF ^{tg} -SCID	1,243 \pm 159	14/15			
Capan-2	Pancreatic	+++	Control SCID	446 \pm 77	12/14	0.0003	54	1 \times 10 ⁶
			HGF ^{tg} -SCID	913 \pm 99	14/14			
HPAF II	Pancreatic	+	Control SCID	316 \pm 54	14/15	0.000001	36	1 \times 10 ⁶
			HGF ^{tg} -SCID	1,459 \pm 183	15/15			

^aThree control SCID mice grew tumors when the mice were kept up to 115 days postinoculation.

^bThe MDA-MB-435 cells have been reported to be a melanoma line instead of breast cancer line.

Reference

- Zhang YW, Staal B, Essenburg C, Su Y, Kang L, West R. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor–dependent fashion to suppress carcinoma growth. *Cancer Res* 2010;70:6880–90.

Published OnlineFirst March 15, 2011.

©2011 American Association for Cancer Research.

doi: 10.1158/0008-5472.CAN-11-0250

Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

Correction: MET Kinase Inhibitor SGX523 Synergizes with Epidermal Growth Factor Receptor Inhibitor Erlotinib in a Hepatocyte Growth Factor–Dependent Fashion to Suppress Carcinoma Growth

Cancer Res 2011;71:2804. Published OnlineFirst March 15, 2011.

Updated version Access the most recent version of this article at:
doi:[10.1158/0008-5472.CAN-11-0250](https://doi.org/10.1158/0008-5472.CAN-11-0250)

Cited articles This article cites 1 articles, 1 of which you can access for free at:
<http://cancerres.aacrjournals.org/content/71/7/2804.full#ref-list-1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://cancerres.aacrjournals.org/content/71/7/2804>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.